Aedra Carla Bufalo

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic–proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m2) and(More)
  • 1